ERNA
Price
$1.56
Change
-$0.17 (-9.83%)
Updated
Aug 1 closing price
Capitalization
11.34M
MDGL
Price
$302.17
Change
-$0.34 (-0.11%)
Updated
Aug 1 closing price
Capitalization
6.71B
3 days until earnings call
Interact to see
Advertisement

ERNA vs MDGL

Header iconERNA vs MDGL Comparison
Open Charts ERNA vs MDGLBanner chart's image
Ernexa Therapeutics
Price$1.56
Change-$0.17 (-9.83%)
Volume$54.69K
Capitalization11.34M
Madrigal Pharmaceuticals
Price$302.17
Change-$0.34 (-0.11%)
Volume$236.79K
Capitalization6.71B
ERNA vs MDGL Comparison Chart in %
Loading...
ERNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ERNA vs. MDGL commentary
Aug 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ERNA is a Hold and MDGL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 02, 2025
Stock price -- (ERNA: $1.56 vs. MDGL: $302.17)
Brand notoriety: ERNA and MDGL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ERNA: 58% vs. MDGL: 74%
Market capitalization -- ERNA: $11.34M vs. MDGL: $6.71B
ERNA [@Biotechnology] is valued at $11.34M. MDGL’s [@Biotechnology] market capitalization is $6.71B. The market cap for tickers in the [@Biotechnology] industry ranges from $213.98B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ERNA’s FA Score shows that 0 FA rating(s) are green whileMDGL’s FA Score has 0 green FA rating(s).

  • ERNA’s FA Score: 0 green, 5 red.
  • MDGL’s FA Score: 0 green, 5 red.
According to our system of comparison, MDGL is a better buy in the long-term than ERNA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ERNA’s TA Score shows that 5 TA indicator(s) are bullish while MDGL’s TA Score has 5 bullish TA indicator(s).

  • ERNA’s TA Score: 5 bullish, 3 bearish.
  • MDGL’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, ERNA is a better buy in the short-term than MDGL.

Price Growth

ERNA (@Biotechnology) experienced а -20.00% price change this week, while MDGL (@Biotechnology) price change was +1.26% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.14%. For the same industry, the average monthly price growth was +15.55%, and the average quarterly price growth was +36.18%.

Reported Earning Dates

ERNA is expected to report earnings on May 07, 2025.

MDGL is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+0.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDGL($6.71B) has a higher market cap than ERNA($11.3M). MDGL YTD gains are higher at: -2.074 vs. ERNA (-64.626). ERNA has higher annual earnings (EBITDA): -33.53M vs. MDGL (-376.15M). MDGL has more cash in the bank: 843M vs. ERNA (1.92M). ERNA has less debt than MDGL: ERNA (2.88M) vs MDGL (120M). MDGL has higher revenues than ERNA: MDGL (317M) vs ERNA (535K).
ERNAMDGLERNA / MDGL
Capitalization11.3M6.71B0%
EBITDA-33.53M-376.15M9%
Gain YTD-64.626-2.0743,116%
P/E RatioN/AN/A-
Revenue535K317M0%
Total Cash1.92M843M0%
Total Debt2.88M120M2%
FUNDAMENTALS RATINGS
ERNA vs MDGL: Fundamental Ratings
ERNA
MDGL
OUTLOOK RATING
1..100
462
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
63
Fair valued
PROFIT vs RISK RATING
1..100
10042
SMR RATING
1..100
10096
PRICE GROWTH RATING
1..100
9559
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ERNA's Valuation (58) in the Medical Specialties industry is in the same range as MDGL (63) in the Pharmaceuticals Other industry. This means that ERNA’s stock grew similarly to MDGL’s over the last 12 months.

MDGL's Profit vs Risk Rating (42) in the Pharmaceuticals Other industry is somewhat better than the same rating for ERNA (100) in the Medical Specialties industry. This means that MDGL’s stock grew somewhat faster than ERNA’s over the last 12 months.

MDGL's SMR Rating (96) in the Pharmaceuticals Other industry is in the same range as ERNA (100) in the Medical Specialties industry. This means that MDGL’s stock grew similarly to ERNA’s over the last 12 months.

MDGL's Price Growth Rating (59) in the Pharmaceuticals Other industry is somewhat better than the same rating for ERNA (95) in the Medical Specialties industry. This means that MDGL’s stock grew somewhat faster than ERNA’s over the last 12 months.

MDGL's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as ERNA (100) in the Medical Specialties industry. This means that MDGL’s stock grew similarly to ERNA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ERNAMDGL
RSI
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 1 day ago
85%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
78%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
82%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
83%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
76%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
76%
Advances
ODDS (%)
Bullish Trend 11 days ago
84%
Bullish Trend 20 days ago
77%
Declines
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 6 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
89%
Bearish Trend 1 day ago
86%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
69%
View a ticker or compare two or three
Interact to see
Advertisement
ERNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HIINX51.64N/A
N/A
Harbor International Investor
MOSSX9.59N/A
N/A
MassMutual Overseas R5
EAERX22.85N/A
N/A
Eaton Vance Stock A
PPVIX11.31N/A
N/A
Principal SmallCap Value II Instl
CMLCX59.10-0.50
-0.84%
American Funds American Mutual 529C

ERNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERNA has been loosely correlated with CGEN. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ERNA jumps, then CGEN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERNA
1D Price
Change %
ERNA100%
-9.83%
CGEN - ERNA
39%
Loosely correlated
+2.07%
MDGL - ERNA
36%
Loosely correlated
-0.11%
IBIO - ERNA
32%
Poorly correlated
-3.09%
SMMT - ERNA
31%
Poorly correlated
+2.65%
CYTK - ERNA
29%
Poorly correlated
-2.52%
More